No products in the cart.
Pre-made Otlertuzumab benchmark antibody ( di-scFv+Fc, anti-CD37 therapeutic antibody, Anti-GP52-40/TSPAN26 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-416
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Otlertuzumab biosimilar, di-scFv+Fc, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Otlertuzumab (TRU-016) is a humanized monoclonal antibody that targets CD37 designed for the treatment of cancer.
| Products Name (INN Index) | Pre-Made Otlertuzumab biosimilar, di-scFv+Fc, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody |
|---|---|
| INN Name | Otlertuzumab |
| Target | CD37 |
| Format | di-scFv+Fc |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Trubion Pharmaceuticals,Aptevo Therapeutics |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Chronic lymphocytic leukaemia,Non-Hodgkin's lymphoma,Peripheral T-cell lymphoma |
| Development Tech | ADAPTIR Monospecific Platform |
| Previous Name | NA |
| Gm Offical Target Name | CD37 |
| Package |
Previous slide
Next slide
